Related Experiment Videos
Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose
E R DeSombre1, B Shafii, R N Hanson
1Ben May Institute, University of Chicago, Illinois 60637.
Cancer Research
|October 15, 1992
Summary
Researchers explored targeted cancer therapy using iodine-123 labeled estrogens to kill estrogen receptor-positive (ER+) cells. This approach delivers Auger electrons directly to cancer cell DNA, showing promise for ER+ cancer treatment.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Estrogen receptor (ER)-containing cancers are a significant therapeutic target.
- Auger electron emitters offer localized cell killing due to their short range.
- Targeted delivery of Auger emitters to cancer cell DNA is crucial for effective therapy.
Purpose of the Study:
- To evaluate the feasibility of using estrogen receptor-directed therapy with Auger electron-emitting ligands.
- To synthesize and assess the radiotoxicity of iodine-123 labeled estrogens for ER+ cancer cells.
- To test the hypothesis that 123I-labeled estrogens can specifically kill ER+ cells.
Main Methods:
- Synthesis of 123I-labeled iodoestrogens using halodestannylation.
- Incubation of ER+ and ER- Chinese hamster ovary cells with 123I-labeled estrogens.
- Cell survival assays to determine radiotoxicity and specificity.
Main Results:
- High specific activity 123I-labeled estrogens were successfully prepared.
- ER+ cells showed a dose-dependent, estradiol-inhibitable reduction in survival.
- ER- cells exhibited minimal sensitivity to the radiotoxicity of the 123I-labeled estrogens.
- Several hundred decays per cell were sufficient for cell killing in ER+ cells.
Conclusions:
- Estrogen receptor-directed therapy with 123I-labeled estrogens is feasible for ER+ cancers.
- This targeted approach demonstrates specific radiotoxicity to ER+ cells.
- The study supports the potential of using Auger electron-emitting estrogens for cancer treatment.